We Offer Worldwide Shipping
Login Wishlist

(-)-Noe’s Reagent

$183

  • Brand : BIOFRON

  • Catalogue Number : BN-O1117

  • Specification : 98%(HPLC)

  • CAS number : 108031-79-4

  • Formula : C24H38O3

  • Molecular Weight : 374.6

  • PUBCHEM ID : 20055568

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1117

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

374.6

Appearance

Botanical Source

Structure Type

Category

SMILES

CC1(C2CCC1(C3C2CC(O3)OC4CC5C6CCC(C5O4)(C6(C)C)C)C)C

Synonyms

Bis[(2S,3aR,4S,7aR)-octahydro-7,8,8-triMethyl-4,7-Methanobenzofuran-2-yl] Ether (-)-noe-lactol dimer/(-)-noe'S/(-)-MBF-OH DIMER/(-)-MBF-OH Dimer(-)-Noe's Reagent/(2S,3AR,ES,7AR)-OCTAHYDRO-7,8,8-TRIMETHYL-4,7-METHANOBENZOFURAN-2-YL ETHER/(-)-NOE-LACTOL(R) DIMER/foropticalresolution/Bis[(2S,3aR,4S,7aR)-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl] Ether

IUPAC Name

(1S,2R,4S,6R,7S)-1,10,10-trimethyl-4-[[(1S,2R,4S,6R,7S)-1,10,10-trimethyl-3-oxatricyclo[5.2.1.02,6]decan-4-yl]oxy]-3-oxatricyclo[5.2.1.02,6]decane

Density

1.12 g/cm3

Solubility

Flash Point

148.7ºC

Boiling Point

435.9ºC at 760 mmHg

Melting Point

150-154ºC(lit.)

InChl

InChl Key

VUDXCBLBKXFCNA-FEFNCVQLSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:108031-79-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30886930

Abstract

Objectives
There has been an increase in the number of women Veterans with service connected disabilities, which are illnesses or injuries incurred or aggravated during military service. We compared military service and disability characteristics in women and men ≤50 years of age.

Methods
This study included 4,029,672 living Veterans who had at least 1 service connected condition and an active award status as of October 1, 2016. The date of last award as well as demographic, military service, and disability characteristics were obtained from the Veterans Benefits Administration (VBA) VETSNET file.

Results
Among 388,947 women Veterans with service connected conditions, almost 60% (n = 231,364) were ≤50 years of age. Roughly 55% of both women and men ≤50 years had a ≥50% combined rating, although there were differences with respect to individual service connected conditions. Women less often had service connected post traumatic stress disorder (23% vs 32%), but more often had major depression (15% vs 7%). While traumatic brain disease was more common in men, migraine headache was much more common in women (32% vs 18%). Less than half had a VA outpatient visit in the previous year.

Conclusions
The findings of significant numbers of younger women with service connected PTSD, depression, or migraine headache should be considered within the context of post deployment health. These findings raise questions regarding outreach to women Veterans who have these conditions, but do not use VA health care.

KEYWORDS

Public health

Title

Characteristics of younger women Veterans with service connected disabilities

Author

Charles Maynard,a,b,∗ Karin Nelson,a,b,c and Stephan D. Fihnb,c

Publish date

2019 Mar;

PMID

31700024

Abstract

Four new derivatives of ketoconazole (Ke) were synthesized: diphenylphosphane (KeP), and phosphane chalcogenides: oxide (KeOP), sulphide (KeSP) and selenide (KeSeP). These compounds proved to be promising antifungal compounds towards Saccharomyces cerevisiae and Candida albicans, especially in synergy with fluconazole. Simulations of docking to the cytochrome P450 14α-demethylase (azoles’ primary molecular target) proved that the new Ke derivatives are capable of inhibiting this enzyme by binding to the active site. Cytotoxicity towards hACSs (human adipose-derived stromal cells) of the individual compounds was studied and the IC50 values were higher than the MIC50 for C. albicans and S. cerevisiae. KeP and KeOP increased the level of the p21 gene transcript but did not change the level of p53 gene transcript, a major regulator of apoptosis, and decreased the mitochondrial membrane potential. Taken together, the results advocate that the new ketoconazole derivatives have a similar mechanism of action and block the lanosterol 14α-demethylase and thus inhibit the production of ergosterol in C. albicans membranes.

Subject terms: Drug discovery and development, Antifungal agents

Title

New diphenylphosphane derivatives of ketoconazole are promising antifungal agents

Author

Rodrigo F. M. de Almeida,1 Filipa C. Santos,1 Krzysztof Marycz,2 Michalina Alicka,2 Anna Krasowska,3 Jakub Suchodolski,3 Jarosław J. Panek,4 Aneta Jezierska,4 and Radosław Starostacorresponding author1,4

Publish date

2019;

PMID

30367868

Abstract

Human babesiosis is an emerging tick-borne parasitic disease and blood transfusion-transmitted infection primarily caused by the apicomplexan parasite, Babesia microti. There is no licensed vaccine for B. microti and the development of a reliable serological screening test would contribute to ensuring the safety of the donated blood supply. The recent sequencing of the B. microti genome has revealed many novel genes encoding proteins that can now be tested for their suitability as subunit vaccine candidates and diagnostic serological markers. Extracellular proteins are considered excellent vaccine candidates and serological markers because they are directly exposed to the host humoral immune system, but can be challenging to express as soluble recombinant proteins. We have recently developed an approach based on a mammalian expression system that can produce large panels of functional recombinant cell surface and secreted parasite proteins. Here, we use the B. microti genome sequence to identify 54 genes that are predicted to encode surface-displayed and secreted proteins expressed during the blood stages, and show that 41 (76%) are expressed using our method at detectable levels. We demonstrate that the proteins contain conformational, heat-labile, epitopes and use them to serologically profile the kinetics of the humoral immune responses to two strains of B. microti in a murine infection model. Using sera from validated human infections, we show a concordance in the host antibody responses to B. microti infections in mouse and human hosts. Finally, we show that BmSA1 expressed in mammalian cells can elicit high antibody titres in vaccinated mice using a human-compatible adjuvant but these antibodies did not affect the pathology of infection in vivo. Our library of recombinant B. microti cell surface and secreted antigens constitutes a valuable resource that could contribute to the development of a serological diagnostic test, vaccines, and elucidate the molecular basis of host-parasite interactions

KEYWORDS

Babesia, Apicomplexa, Vaccine, Serology, Diagnostics

Title

A library of recombinant Babesia microti cell surface and secreted proteins for diagnostics discovery and reverse vaccinology

Author

Catherine M. Elton,a Marilis Rodriguez,b Choukri Ben Mamoun,c Cheryl A. Lobo,b and Gavin J. Wrighta,⁎

Publish date

2019 Feb;


Description :

Empty ...